NGGT006
Phase 1Small molecule
NGGT006 is one of 22 small molecule programs targeting Hypercholesterolemia. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Hypercholesterolemia
#DrugCompanyPhaseTrials
1Crestor
AstraZenecaApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zocor
OOrganon and Co
Approved
Leqvio
NovartisApproved
Livalo
MMedicure
Approved
Praluent
RegeneronPhase 3
Lesinurad
EEsperion Therapeutics, Inc.
Approved
Niacor
AbbVieApproved
Tricor
JJagotec
Approved
Questran
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NGGT006. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- SSuzhou Municipal Hospital